What the FDA labels say about taking them together
Darunavir and everolimus
Darunavir's FDA label of August 29, 2025 names everolimus in its drug interactions section; the everolimus labels PlainMeds reads (2) do not name darunavir. The darunavir label: “Immunosuppressant/neoplastic: everolimus Co-administration of everolimus and PREZISTA/ritonavir is not recommended. irinotecan Discontinue PREZISTA/ritonavir at least 1 week prior to starting irinotecan therapy.”
Check it at the source: the darunavir FDA label on DailyMed (effective August 29, 2025, Janssen Products LP); the everolimus FDA label on DailyMed (effective June 1, 2026, Novartis Pharmaceuticals Corporation).
What does the darunavir label say about everolimus?
Darunavir label, drug interactionsImmunosuppressant/neoplastic: everolimus Co-administration of everolimus and PREZISTA/ritonavir is not recommended. irinotecan Discontinue PREZISTA/ritonavir at least 1 week prior to starting irinotecan therapy.
Source: FDA drug label (PREZISTA), Janssen Products LP, effective August 29, 2025 (SPL set 814301f9-c990-46a5-b481-2879a521a16f), via openFDA; the full label on DailyMed
What does the everolimus label say about darunavir?
Everolimus's label (effective June 1, 2026) and its 1 other brand-application label do not name darunavir in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Afinitor), Novartis Pharmaceuticals Corporation, effective June 1, 2026 (SPL set 2150f73a-179b-4afc-b8ce-67c85cc72f04), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Darunavir | Everolimus | |
|---|---|---|
| Labeled for | HIV | Breast cancer, Seizures and epilepsy, Organ transplant rejection |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | $1.16 per tablet 600 mg tablet | $26.32 per tablet 10 mg tablet |
| Shortage now | No current entry | A presentation being discontinued |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once